Blackstone Inc. and TPG Inc. are in advanced negotiations to acquire Hologic Inc. in a deal that could value the medical device maker at more than $17 billion including debt, according to people familiar with the matter.
A transaction could be announced in the coming days, said the people, who asked not to be identified because the talks are private. The parties are currently discussing a price of above $75 a share, they said.
Hologic shares jumped about 6 percent in late trading after Bloomberg reported on the discussions. They had closed 2 percent higher at $69.85 Friday in New York, giving the company a market value of about $15.5 billion.
A final agreement hasn’t been reached and the talks could still fall apart, the people said.
Representatives of Blackstone and TPG declined to comment, as did a spokesperson for Marlborough, Massachusetts-based Hologic.
Bloomberg News reported last month that the private equity firms had reengaged with the company’s board.
Hologic is focused on women’s health, and develops diagnostic solutions for breast and cervical cancer, as well as infectious diseases like COVID-19. Any deal for the company could end up becoming one of the biggest private equity takeovers globally this year, according to data compiled by Bloomberg.
With assistance from Manuel Baigorri.
var oneTrustActive = true;
var oneTrustConsentObj;
try {
oneTrustConsentObj = JSON.parse(window.localStorage.getItem(‘consent_one_trust_bgmp’) || ‘{}’);
} catch (err) {
oneTrustConsentObj = {};
}
// Default to granted consent
var consent=”grant”
// FB script decleration
!function(f,b,e,v,n,t,s) {
if(f.fbq)return;n=f.fbq=function(){n.callMethod?n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s);
}
(window,document,’script’, ‘https://connect.facebook.net/en_US/fbevents.js’);
if (oneTrustActive && oneTrustConsentObj && oneTrustConsentObj.C0004 === false) {
consent=”revoke”;
}
// We need to call consent before we run init and track
fbq(‘consent’, consent);
fbq(‘set’, ‘autoConfig’, ‘false’, ‘884869448226452’);
fbq(‘set’, ‘autoConfig’, ‘false’, ‘493062270895851’);
fbq(‘init’, ‘884869448226452’);
fbq(‘track’, ‘PageView’);